Candel Therapeutics, Inc.
CADLHealthcare|Biotechnology|US
$8.75
+0.71 (+8.83%)
DCF Value
$2.20
Tangible Book / Share
$1.70
Cash / Share
$2.72
Clinical Trials (14)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07660094 Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) | Non-squamous, Non-Small Cell Lung Cancer | P3 | Recruiting | 500 | RCT, Open-label | Aglatimagene Besadenovec, Valacyclovir, Pembrolizumab, Docetaxel |
| NCT01436968 Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer | Prostate Cancer | P3 | Active | 711 | RCT, Double-blind | Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir |
| NCT04495153 CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC | Non Small Cell Lung Cancer | P2 | Active | 90 | Open-label | Aglatimagene besadenovec, Valacyclovir, Standard of Care anti-PD-1/PD-L1 (ICI), Chemotherapy |
| NCT07332000 A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma) | P2 | Recruiting | 45 | Open-label | aglatimagene besadenovec + valacyclovir |
| NCT02768363 Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) | Prostate Cancer | P2 | Active | 187 | RCT, Double-blind | aglatimagene besadenovec, placebo, valacyclovir |
| NCT03152318 A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | Malignant Glioma of Brain, Astrocytoma | P1 | Active | 62 | Open-label | rQNestin, Cyclophosphamide |
| NCT00589875 Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | Malignant Glioma, Glioblastoma Multiforme | P2 | Completed | 52 | Open-label | CAN-2409, Valacyclovir, Temozolomide |
| NCT02446093 Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | P2 | Unknown | 54 | RCT, Open-label | Aglatimagene besadenovec |
| NCT03576612 GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas | Glioma, Malignant | P1 | Completed | 41 | Open-label | AdV-tk, Valacyclovir, Temozolomide, Nivolumab |
| NCT00634231 A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors | Malignant Glioma, Recurrent Ependymoma | P1 | Completed | 8 | Open-label | AdV-tk, valacyclovir |
| NCT00751270 Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | Malignant Glioma, Glioblastoma Multiforme | P1 | Completed | 15 | Open-label | AdV-tk, Valacyclovir |
| NCT00638612 AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) | Pancreatic Adenocarcinoma, Pancreatic Cancer | P1 | Completed | 27 | Open-label | AdV-tk, Valacyclovir |
| NCT01997190 Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion | Malignant Pleural Effusion, Lung Cancer | P1 | Completed | 19 | Open-label | AdV-tk + valacyclovir |
| NCT03131037 Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer | Lung Cancer | P1 | Completed | 12 | Open-label | CAN-2409 + valacyclovir |